News & Views
NovaBiotics Wins Life Science Business Leadership Award
Mar 05 2014 Read 978 Times
NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company was awarded the Life Science Business Leadership Award at the Scottish Enterprise Life Sciences Annual Dinner. CEO, Dr Deborah O’Neil, was recognised for her leadership and vision which has been instrumental in the growth of NovaBiotics. After 11 years of work and three years of contract development, Deborah and her team secured an exclusive agreement with Taro Pharmaceuticals to licence and co-develop the Company’s lead product Novexatin® in August 2013, which is among the largest deals reached in the Scottish life science arena in recent years. NovaBiotics’ unique and ambitious strategy has also been recognised.
Dr O’Neil said: “I am proud of what NovaBiotics has achieved thus far and the Life Science Business Leadership Award reflects this. Our deal with Taro Pharmaceuticals is a huge success for the company and demonstrates industry confidence in our approach. By sticking to our business model and focusing on the results that our research was producing, we have created a solid foundation for our products and vision. Through all of this, we have been very fortunate to have been supported by organisations like the Scottish Enterprise, funding bodies, excellent, sector-specific mentors and a very talented team.”
Julia Brown, Director of Life and Chemical Sciences, Scottish Enterprise, said: “Congratulations to Dr O’Neil and to NovaBiotics. This is a fantastic achievement and the company’s continued success, including its international outlook, is very much testament to the innovation, drive and vision that Dr O’Neil demonstrates on a daily basis.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...
View all digital editions
Dec 13 2019 Kathmandu, Nepal
Jan 25 2020 San Diego, CA, USA
Jan 27 2020 Dubai, UAE
Jan 29 2020 Tokyo, Japan
Jan 29 2020 Ghent, Belgium